KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arbutus Biopharma (ABUS) Share-based Compensation: 2010-2025

Historic Share-based Compensation for Arbutus Biopharma (ABUS) over the last 16 years, with Sep 2025 value amounting to $1.3 million.

  • Arbutus Biopharma's Share-based Compensation fell 41.53% to $1.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.3 million, marking a year-over-year decrease of 19.32%. This contributed to the annual value of $9.0 million for FY2024, which is 3.39% down from last year.
  • As of Q3 2025, Arbutus Biopharma's Share-based Compensation stood at $1.3 million, which was up 46.18% from $864,000 recorded in Q2 2025.
  • Arbutus Biopharma's Share-based Compensation's 5-year high stood at $3.6 million during Q1 2025, with a 5-year trough of $864,000 in Q2 2025.
  • Its 3-year average for Share-based Compensation is $2.2 million, with a median of $2.1 million in 2023.
  • Over the last 5 years, Arbutus Biopharma's Share-based Compensation had its largest YoY gain of 76.96% in 2025, and its largest YoY loss of 72.83% in 2025.
  • Quarterly analysis of 5 years shows Arbutus Biopharma's Share-based Compensation stood at $1.4 million in 2021, then rose by 16.49% to $1.7 million in 2022, then increased by 3.36% to $1.7 million in 2023, then decreased by 5.28% to $1.6 million in 2024, then tumbled by 41.53% to $1.3 million in 2025.
  • Its last three reported values are $1.3 million in Q3 2025, $864,000 for Q2 2025, and $3.6 million during Q1 2025.